Abstract
Radiotherapy for widespread bone metastasis results in severe hematological toxicity. A 71-year-old male was diagnosed with metastatic hormone-sensitive prostate cancer (cT4N1M1b) and treated with apalutamide and degarelix. Concurrently, palliative radiation therapy was sequentially initiated for the 1st, 5th, and 10th thoracic vertebrae and right femur. On day 35 after treatment, severe neutropenia necessitated treatment interruption and required 23 days for neutrophil recovery with a granulocyte colony-stimulating factor agent. Owing to the severe hematologic toxicity caused by extensive radiation therapy for multiple bone lesions, treatment prioritization by lesion and avoiding irradiation of the red bone marrow is essential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
